BridgeMD
Prevention study for Cirrhosis, Liver
Official title EGCG for Hepatocellular Carcinoma Chemoprevention
ClinicalTrials.gov ID: NCT06015022
What this study is testing
What is Epigallocatechin gallate (EGCG)?
Epigallocatechin gallate (EGCG) is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for cirrhosis, liver.
Also referred to as Teavigo.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults (≥ 18 years-old)
- Clinically and/or histologically diagnosed cirrhosis
- No active hepatic decompensation
- No prior history of HCC
- Adequate hematologic, hepatic, and renal function
You likely can't join if
- Prior or ongoing use of EGCG
- History of adverse reaction to green tea products
- Severe obesity (BMI \> 40 kg/m2)
- Active drinking
- EGCG treatment \<4 weeks or \<80% of planned regimen at the end of week 4
- HCC development during the study
See the full eligibility criteria
- Adults (≥ 18 years-old)
- Clinically and/or histologically diagnosed cirrhosis
- No active hepatic decompensation
- No prior history of HCC
- Adequate hematologic, hepatic, and renal function
- Karnofsky performance status score ≥70
- Both sexes and all racial/ethnic groups will be considered
- FIB-4 index \> 3.25
- High-risk PLSec at baseline
- Absence of HLA-B\ 35:01
- Prior or ongoing use of EGCG
- History of adverse reaction to green tea products
- Severe obesity (BMI \> 40 kg/m2)
- Active drinking
- EGCG treatment \<4 weeks or \<80% of planned regimen at the end of week 4
- HCC development during the study
The study team makes the final eligibility decision.
Where it's taking place
- Dallas, Texas, United States
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dallas, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.